Ballicules.com

Safinamide

XADAGO

What it isReversible MAO-B inhibitor that also blocks sodium channels and glutamate release; Parkinson OFF episodes.

Why this oneThe dual mechanism adds glutamatergic modulation, which the other MAO-B inhibitors lack.

What limits itDyskinesia can worsen. Selectivity is lost at higher doses; avoid with other serotonergic drugs.

FDA label

FDA dosingPopulationStartTargetMax
Parkinson's disease (adjunct to levodopa/carbidopa, 'off' episodes)Adults50 mg QD100 mg QD after 2 weeks100 mg QD

Titration After 2 weeks may increase from 50 mg to 100 mg QD.

Renal Undefined

Hepatic Moderate (Child-Pugh B): max 50 mg QD. Severe (Child-Pugh C): contraindicated.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate human data; animal studies show developmental toxicity including teratogenicity.

Lactation Undefined

NO BOXED WARNINGS

Principal riskDyskinesia can worsen

Cost, est. cash$300–$5,000/month

Generic entry2023

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability1 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilityOrthostasis, hallucinations, dyskinesia and impulse-control symptoms; abrupt withdrawal can be hazardous.

Mechanism of action: Safinamide ballicule

Safinamide ballicule: receptor binding, kinetics and half-life diagram

Open Safinamide in the interactive console ↗

Memory aids: mascots and interaction avatars

Safinamide XADAGO mascot mnemonic cartoon
“DA (dopamine) goes (in the) fin safe”
Mao Zedong → MAO inhibitor

Open Safinamide in the interactive console ↗